Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials

References

• Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE, et al. Update on new biologics for intractable eosinophilic asthma: impact of Reslizumab. Am J Respir Crit Care Med 2004;170:836–844.
   PubMed Web of Science ®Google Scholar
• Hermosa JLR, Sánchez CB, Rubio MC, Mínguez MM, Walther JL. Factors associated with the control of severe asthma. J Asthma 2010;47:124–130.
   PubMed Web of Science ®Google Scholar
• Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139–1151. doi:10.1016/j.rmed.2006.03.031
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Liu Y-J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006;203:269–273. doi:10.1084/jem.20051745
   PubMed Web of Science ®Google Scholar
• Larché M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003;111:450–463; quiz 464. http://www.ncbi.nlm.nih.gov/pubmed/12642820.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546–3556. doi:10.1172/JCI36130
   PubMed Web of Science ®Google Scholar
• Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep 2013;13:415–420. doi:10.1007/s11882-013-0373-9
   PubMed Web of Science ®Google Scholar
• Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. N Engl J Med 2013;368:2511–2513. doi:10.1056/NEJMe1305426
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378:2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378:2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31–44. doi:10.1016/S0140-6736(16)30307-5
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455–2466. doi:10.1056/NEJMoa1304048
   PubMed Web of Science ®Google Scholar
• Sahota J, Robinson DS. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab. Drug Des Devel Ther 2018;12:1173–1181. doi:10.2147/DDDT.S109489
   PubMed Web of Science ®Google Scholar
• Egan R, Athwal D, Bodmer M, Carter J, Chapman R, Choua C-C, Coxa M, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 2011;49:779–790. doi:10.1055/s-0031-1300502
   Google Scholar
• Robinson DS. Mepolizumab treatment for asthma. Expert Opin Biol Ther 2013;13:295–302. doi:10.1517/14712598.2012.725717
   PubMed Web of Science ®Google Scholar
• Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012;42:712–737. doi:10.1111/j.1365-2222.2011.03854.x
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 2016;150:799–810. doi:10.1016/j.chest.2016.03.018
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016;150:789–798. doi:10.1016/j.chest.2016.03.032
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (London, England) 2012;380:651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet (London, England) 2016;388:2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 2016;388:2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar